Novistig (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide and Neostigmine methylsulfate, the active ingredients in Novistig, are anticholinergic and acetylcholinesterase inhibitor agents presented as an injectable solution for intravenous use. They are employed to reverse non‑depolarizing neuromuscular blockade after surgery in adult patients.

GNH USA supplies Novistig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Novistig, containing glycopyrronium bromide and neostigmine methylsulfate, is used in the peri‑operative setting to address residual neuromuscular blockade.

- Reversal of non‑depolarizing neuromuscular blockade: restores normal muscle function after surgery. - Post‑operative residual curarization: reduces lingering muscle weakness following anesthesia. - Facilitation of spontaneous breathing: enables patients to resume adequate ventilation after neuromuscular blocker use.

Common Side Effects: - Dry mouth: reduced salivary flow may cause discomfort. - Bradycardia: slowing of heart rate can occur during administration. - Nausea: patients may feel queasy after dosing. - Muscle fasciculations: transient twitching of skeletal muscles.

Serious or Rare Side Effects: - Bronchospasm: airway constriction requiring immediate attention. - Severe hypotension: marked drop in blood pressure that may be life‑threatening.

Novistig should be administered only under close monitoring of neuromuscular function and cardiovascular status. - Assess neuromuscular function before dosing: ensure adequate recovery from blockade. - Monitor heart rate and blood pressure: watch for bradycardia or hypotension. - Avoid in severe asthma: risk of bronchospasm may be heightened. - Use with caution in renal impairment: drug clearance may be reduced. - Adjust dose in elderly patients: increased sensitivity to anticholinergic effects. - Store at ambient temperature: keep in original container, protect from moisture.

Novistig may interact with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Other anticholinergic agents: additive anticholinergic burden may cause severe dry mouth or urinary retention. - Additional acetylcholinesterase inhibitors: risk of cholinergic excess leading to bradycardia or muscle cramps. - Beta‑blockers: may potentiate bradycardic effects.

Moderate Interactions (Monitor Closely): - Respiratory depressant anesthetics: combined effect may impair ventilation. - Concurrent neuromuscular blocking agents: dose adjustments may be required. - Diuretics: electrolyte shifts can influence neuromuscular transmission.